Oral and Parenteral Delivery of Poorly Soluble Compounds – Still a Mystery?



11 - 12 March 2020 Munich, Germany

Course no. 6807



Research and Development

Target group

Scientists from academia and industry, formulation experts, managers in pharmaceutical research and development, production, quality assurance, project management, product management and life cycle management.



A seminar organised by the APV focus group Drug Delivery

Objectives and content

Over the last two decades the number of oral drug candidates in discovery and development, which are poorly water soluble, and thus show poor bioavailability, has tremendously increased. In parallel, expertise was developed on how to overcome this challenge and many different technologies have been discovered. This makes it quite difficult for a formulation scientist nowadays to get or keep the overview including all pros and cons of the respective approaches ready to hand in order to select the appropriate one for a specific molecule. This two day conference will provide you with an insight into human physiology and its implications to poorly soluble compounds, introduce you to the most important technologies used, but also mention emerging approaches and of course present you a summary of commercial products and the formulation approaches applied.

In recent years some shift from oral to parenteral administered compounds is taking place. This is not only due to the increasing number of biological compounds (New Biological Entities), but also more and more poorly soluble small molecules (New Chemical Entities) arrive at the formulator's lab bench. Half a day is scheduled to introduce you to the options of formulation development for parenteral drug candidates, which are poorly water soluble. An excursion into the world of NBE development and the associated solubility issues will complete the picture.

At the end of two intensive days of immersing in formulation development of poorly soluble compounds, you will return home with a profound knowledge on how to proceed with this type of compounds and with the certainty, that it is still a challenging but manageable job and not a mystery anymore.

Moderators



Georg Boeck

Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany



Susanne Page

F. Hoffmann-La Roche AG, Basel, Switzerland



Simone Wengner

Catalent Germany Eberbach GmbH, Eberbach, Germany

Programme

Wednesday, 11 March 2020, 08:45 - 17:00 Uhr

Opening remarks

Georg Boeck, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany

Formulation approaches for poorly and pH dependent water soluble drug substances

Dieter Becker, Vivo Drug Delivery GmbH, Freiburg, Germany

Mesoporous silica based ASDs in comparison to polymer based systems

Guy van den Mooter, KU Leuven, Leuven, Belgium

Co-amorphous drug delivery systems

Thomas Rades, University of Copenhagen, Copenhagen, Denmark

Long-term stability of amorphous solid dispersions

Gabriele Sadowski, Technische Universität Dortmund, Dortmund, Germany

Key considerations in extrusion development for successful marketing applications

Benedikt Steitz, Oliver Heinzerling, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

GI physiology: insights from imaging studies and implications for formulation development Werner Weitschies, University of Greifswald, Greifswald, Germany

Value of biorelevant media for measuring solubility and developing biopredictive dissolution methods Jennifer Dressman, University of Frankfurt, Frankfurt, Germany

In vitro models for evaluating the impact of gastrointestinal transfer on intraluminal performance of orally administered poorly soluble drugs

Christos Reppas, University of Athens, Athens, Greece

Social networking event

Thursday, 12 March 2020, 08:45 - 16:15 Uhr

Opening remarks

Susanne Page, F. Hoffmann-La Roche AG, Basel, Switzerland

Formulating poorly soluble compounds in lipid systems and regulatory aspects

Sivacharan Kollipara, Novartis Healthcare Pvt. Ltd., Hyderabad, India

Poorly soluble compound development - The current and future state

Kurt Sedo, PharmaCircle, Encinitas, United States

Review of solubilizing formulations for parenteral administration of NCEs Peter van Hoogevest, Lipoid GmbH, Ludwigshafen, Germany

Influence of intravenous lipid based formulations on the pharmacokinetics of poorly water soluble drug substances Alfred Fahr, University of Jena, Jena, Germany

Development of parenteral depot formulations Rene Holm, Janssen Pharmaceutica, Beerse, Belgium

Cyclodextrins in parenteral formulations Thorsteinn Loftsson, University of Iceland, Reykjavik, Iceland

Challenges with "poor solubility" in the formulation development of NBEs Karlonie Bechthold-Peters, Novartis Pharma AG, Basel, Switzerland

Closing remarks Simone Wengner Catalent Germany Eberbach GmbH, Eberbach, Germany

Registration by fax +49 6131 97 69 69 or by email apv@apv-mainz.de



Location		Registration fee		Regis	tration	Hotelr	reservation
Maritim Hotel München Goethestraße 7 80336 München Germany		Industry Authority/University Students* (free of VAT according to § Coffee breaks, luncheon, o electronic proceedings incl	1490 EUR 745 EUR 178 EUR 4,22 UStG) dinner and uded.	APV-Geschäftsstelle Kurfürstenstraße 59 55118 Mainz/Germany Phone: 0049 6131 97 69 0 Fax: 0049 6131 97 69 69 E-mail: apv@apv-mainz.de Web: www.apv-mainz.de You will receive a confirmation of your registration with the invoice.		Maritim Hotel München Goethestraße 7 80336 München Germany phone 0049 89 55235 0 mail info.mun@maritim.de Participants should make their own hotel reservation referring to the APV seminar. Deadline for special conference rate: 14 January 2020. Special rate: Single room incl. breakfast from 134,00 € per night. Mainz, November 2019	
Date Course no.: 6807 from 11 March 2020 to 12 March 2020	08:45 h 16:15 h	* Limited places for full tin students available; written must be submitted.	ne evidence				

Oral and Parenteral Delivery of Poorly Soluble Compounds, 11 - 12 March 2020, Munich, Germany, Course no. 6807

Registration

Registration As soon as you have found a seminar of your interest, it is very easy to register for it via fax, e-mail or online. We will process your registration promptly and certainly are available for any questions that may arise.	Title, first name, last name *					
Registration confirmation After your registration was successfully processed, you will receive a confirmation.	Company name *					
Before the event	Street/no. or P.O. box *					
important information about the seminar, such as time, date, addresses etc.	Location					
After the event You will receive a certificate confirming your	Zip-code and city *					
to fill-in our evaluation sheet to make sure we get better every time.	Phone					
Follow-up After the event, we are open to receive any suggestions and critique that might arise during the seminar and	E-mail-address participant *					
will certainly help you with further questions you may have.	Order no. and/or billing address					
Declaration of consent in respect of data protection						
By registering for this seminar, I agree that the APV uses my data for the purpose of processing the order and provides me with all relevant	Pay via invoice					
information.	(You will receive further payment information with the invoice)					
I also agree that APV may contact me for the purpose of exchanging similar information by email or post.	Date * Signature *					
Your data will not be shared with third parties. You	* Mandatory					
have a right of withdrawal at any time without giving reasons.	Arbeitsgemeinschaft für Pharmazeutisc Verfahrenstechnik e.V.	he	APV-Geschäftsstelle Kurfürstenstraße 59 55118 Mainz/Germany			
All other information can be found in our privacy policy (www.apv-mainz.de/en/imprint/data-protection-	Gemeinnütziger wissenschaftlicher Verein International Association for Pharmaceutical Technolo		Phone: 0049 6131 97 69 0			
statement/).	www.apv-mainz.de/en	ax: 0049 6131 97 69 69 -mail apv@apv-mainz.de				